A Study Evaluating TRIV-573 in Atopic Dermatitis

Sponsor
Triveni Bio
Study ID
NCT07782333
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • TRIV-573 — DRUG
    TRIV-573 (Subcutaneous injection)
  • Placebo — DRUG
    Placebo (Matching Placebo subcutaneous injection)

Study Details

The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.

Key Dates

First listed
Aug 24, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2027
Completion
Feb 29, 2028

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: TRIV-573
  • Placebo Comparator: Placebo

Primary Outcome Measure

Percentage of participants with improvement of AD [ Time Frame: Baseline through Week 16 ]

Central Contacts

Find similar trials

Nationwide
Atopic dermatitis / eczema trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies